TGF-β1 exposure induces epithelial to mesenchymal transition both in CSCs and non-CSCs of the A549 cell line, leading to an increase of migration ability in the CD133+ A549 cell fraction

Cell Death and Disease

Volumn 4, Issue 5, 2013, Pages

  Tirino, V ^a   Camerlingo, R ^b   Bifulco, K ^b   Irollo, E ^b   Montella, R ^b   Paino, F ^a   Sessa, G ^b   Carriero, M V ^b   Normanno, N ^b   Rocco, G ^c   Pirozzi, G ^b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Cancer stem cells; Epithelial'mesenchymal transition; Migration; TGF 1

Indexed keywords

CD133 ANTIGEN; CYTOKERATIN; GELATINASE B; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR SLUG; TRANSFORMING GROWTH FACTOR BETA1; UVOMORULIN; VIMENTIN; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; PEPTIDE; POU5F1 PROTEIN, HUMAN; SNAIL FAMILY TRANSCRIPTION FACTORS; TRANSCRIPTION FACTOR;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER STEM CELL; CELL FRACTIONATION; CELL LEVEL; CELL MOTILITY; CELL STIMULATION; CELL SUBPOPULATION; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIDE POPULATION CELL; TRANSCELLULAR CELL MIGRATION; UPREGULATION; WILD TYPE; CELL MOTION; DRUG EFFECTS; GENETICS; LUNG TUMOR; METABOLISM; NON SMALL CELL LUNG CANCER; PATHOLOGY; TUMOR CELL LINE;

ANTIGENS, CD; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL MOVEMENT; EPITHELIAL-MESENCHYMAL TRANSITION; GLYCOPROTEINS; HUMANS; LUNG NEOPLASMS; MATRIX METALLOPROTEINASE 9; NEOPLASTIC STEM CELLS; OCTAMER TRANSCRIPTION FACTOR-3; PEPTIDES; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA1; VIMENTIN;

EID: 84879375174     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.144     Document Type: Article

References (42)

1. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006; 24: 4539-4544.
2. World Health Organization. International Agency for Research on Cancer. World Cancer Report. IARC Press: Lyon, 2008.
3. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60: 277-300.
4. Gavert N, Ben-Ze'ev A. Epithelial-mesenchymal transition and the invasive potential of tumors. Trends Mol Med 2008; 14: 199-209.
5. Nawshad A, Lagamba D, Polad A, Hay ED. Transforming growth factor-b signaling during epithelial-mesenchymal transformation: implications for embryogenesis and tumor metastasis. Cells Tissues Organs 2005; 179: 11-23.
6. Seton-Rogers S. Metastasis: signalling in transit. Nat Rev Cancer. 2011; 12: 4.
7. Nguyen DX, Bos PD, Massagué J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009; 9: 274-284.
8. Gomes LR, Terra LF, Sogayar MC, Labriola L. Epithelial-mesenchymal transition: implications in cancer progression and metastasis. Curr Pharm Biotechnol 2011; 12: 1881-1890.
9. Labelle M, Begum S, Hynes R O. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 2011; 20: 576-590.
10. Bierie B, Moses HL. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006; 6: 506-520.
11. Heldin CH, Landstroöm M, Moustakas A. Mechanism of TGF-b signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition. Curr Opin Cell Biol 2009; 21: 166-716.
12. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111.
13. Vermeulen L, Sprick MR, Kemper K, Stassi G, Medema JP. Cancer stem cells-old concepts, new insights. Cell Death Differ 2008; 15: 947-958.
14. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005; 5: 275-284.
15. Tirino V, Camerlingo R, Franco R, Malanga D, La Rocca A, Viglietto G et al. The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. Eur J Cardiothorac Surg 2009; 36: 446-453.
16. Yin S, Li J, Hu C, Chen X, Yao M, Yan M et al. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer 2007; 120: 1444-1450.
17. Hirschmann-Jax C, Foster AE, Wulf GG, Goodell MA, Brenner MK. A distinct "side population" of cells in human tumor cells: implications for tumor biology and therapy. Cell Cycle 2005; 4: 203-520.
18. Tirino V, Desiderio V, Paino F, De Rosa A, Papaccio F, La Noce M et al. Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization. FASEB J 2013; 27: 13-24.
19. Collura A, Marisa L, Trojan D, Buhard O, Lagrange A, Saget A et al. Extensive characterization of sphere models established from colorectal cancer cell lines. Cell Mol Life Sci 2012; 70: 729-742.
20. Pirozzi G, Tirino V, Camerlingo R, Franco R, La Rocca A, Liguori E et al. Epithelial to mesenchymal transition by TGF-b1 induction increases stemness characteristics in primary non small cell lung cancer cell line. PLoS One 2011; 6: e21548.
21. Christofori G. New signals from the invasive front. Nature 2006; 441: 444-450.
22. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 2006; 127: 679-695.
23. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 2006; 172: 973-981.
24. Gavert N, Ben-Ze'ev A. Epithelial-mesenchymal transition and the invasive potential of tumors. Trends Mol Med 2008; 14: 199-209.
25. Rosivatz E, Becker I, Specht K, Fricke E, Luber B, Busch R et al. Differential expression of the epithelial-mesenchymal transition regulators Snail, SIP1, and Twist in gastric cancer. Am J Pathol 2002; 161: 1881-1891.
26. Yang Z, Zhang X, Gang H, Li X, Li Z, Wang T et al. Up-regulation of gastric cancer cell invasion by Twist is accompanied by N-cadherin and fibronectin expression. Biochem Biophys Res Commun 2007; 358: 925-930.
27. Miettinen PJ, Ebner R, Lopez AR, Derynck R. TGF-b induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. J Cell Biol 1994; 127: 2021-2036.
28. Kasai H, Allen JT, Mason RM, Kamimura T, Zhang Z. TGF-b1 induces human alveolar epithelial to mesenchymal cell transition (EMT). Respir Res 2005; 6: 56.
29. Brown KA, Aakre ME, Gorska AE, Price JO, Eltom SE, Pietenpol JA et al. Induction by transforming growth factor-b1 of epithelial to mesenchymal transition is a rare event in vitro. Breast Cancer Res 2004; 6: R215-R231.
30. Shintani Y, Maeda M, Chaika N, Johnson KR, Wheelock MJ. Collagen I promotes epithelial-to-mesenchymal transition in lung cancer cells via transforming growth factor-b signaling. Am J Respir Cell Mol Biol 2008; 38: 95-104.
31. Hui-Jun Zhang, He-Yong Wang, Hong-Tao Zhang, Jin-Mei Su, Jun Zhu, Hai-Bing Wang et al. Transforming growth factor-b1 promotes lung adenocarcinoma invasion and metastasis by epithelial-to-mesenchymal transition. Mol Cell Biochem 2011; 355: 309-314.
32. Ko H, So Y, Jeon H, Jeong MH, Choi HK, Ryu SH, Lee SW, Yoon HG, Choi KC. TGF-b1-induced epithelial-mesenchymal transition and acetylation of Smad2 and Smad3 are negatively regulated by EGCG in Human A549 lung cancer cells. Cancer Lett 2013. pii: S0304-3835(13)00130-4. doi:10.1016/j.canlet.2013.02.018.
33. May CD, Sphyris N, Evans KW, Werden SJ, Guo W, Mani SA. Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression. Breast Cancer Res 2011; 13: 202.
34. Maeda M, Johnson KR, Wheelock MJ. Cadherin switching: essential for behavioral but not morphological changes during an epithelium-to-mesenchyme transition. J Cell Sci 2005; 118: 873-887.
35. Harigopal M, Berger AJ, Camp RL, Rimm DL, Kluger HM. Automated quantitative analysis of E-cadherin expression in lymph node metastases is predictive of survival in invasive ductal breast cancer. Clin Cancer Res 2005; 11: 4083-4089.
36. Rees JR, Onwuegbusi BA, Save VE, Alderson D, Fitzgerald RC. In vivo and in vitro evidence for transforming growth factor-b1-mediated epithelial to mesenchymal transition in esophageal adenocarcinoma. Cancer Res 2006; 66: 9583-9590.
37. Rosivatz E, Becker I, Specht K, Fricke E, Luber B, Busch R et al. Differential expression of the epithelial-mesenchymal transition regulators Snail, SIP1, and Twist in gastric cancer. Am J Pathol 2002; 161: 1881-1891.
38. Zheng S, Chang Y, Hodges KB, Sun Y, Ma X, Xue Y, Williamson SR, Lopez-Beltran A, Montironi R, Cheng L. Expression of KISS1 and MMP-9 in non-small cell lung cancer and their relations to metastasis and survival. Anticancer Res 2010; 30: 713-718.
39. Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T. Opinion: migrating cancer stem cells-an integrated concept of malignant tumour progression. Nat Rev Cancer 2005; 5: 744-749.
40. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-715.
41. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 1996; 183: 1797-1806.
42. Carriero MV, Longanesi-Cattani I, Bifulco K, Maglio o, Lista L, Barbieri A et al. Structure-based design of an urokinase-type plasminogen activator receptor-derived peptide inhibiting cell migration and lung metastasis. Mol Cancer Ther 2009; 8: 2708-2717.